DeSantis Anita H, Buss Kristina, Coker Keaton M, Pasternak Brad A, Chi Jinhua, Patterson Jeffrey S, Gu Haiwei, Jurutka Peter W, Sandrin Todd R
School of Mathematical and Natural Sciences, Arizona State University, 4701 W. Thunderbird Rd, Glendale, AZ 85306, USA.
Biosciences Core, Arizona State University, 1001 S. McAllister Ave, Tempe, AZ 85281, USA.
Biomolecules. 2025 May 21;15(5):746. doi: 10.3390/biom15050746.
Inflammatory bowel disease (IBD), which includes Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic gastrointestinal (GI) disorder affecting 1 in 100 people in the United States. Pediatric IBD (PIBD) is estimated to impact 15 per 100,000 children in North America. Factors such as the gut microbiome (GM), genetic predisposition to the disease, and certain environmental factors are thought to be involved in pathogenesis. However, the pathophysiology of IBD is incompletely understood, and diagnostic biomarkers and effective treatments, particularly for PIBD, are limited. Recent work suggests that these factors may interact to influence disease development, and multiomic approaches have emerged as promising tools to elucidate the pathophysiology. We employed metagenomics, metabolomics- and metatranscriptomics-based approaches to examine the microbiome, its genetic potential, and its activity to identify factors associated with PIBD. Metagenomics-based analyses revealed pathways such as octane oxidation and glycolysis that were differentially expressed in UC patients. Additionally, metatranscriptomics-based analyses suggested enrichment of glycan degradation and two component systems in UC samples as well as protein processing in the endoplasmic reticulum, ribosome, and protein export in CD and UC samples. In addition, metabolomics-based approaches revealed patterns of differentially abundant metabolites between healthy and PIBD individuals. Interestingly, overall microbiome community composition (as measured by alpha and beta diversity indices) did not appear to be associated with PIBD. However, we observed a small number of differentially abundant taxa in UC versus healthy controls, including members of the Classes and as well as members of the Family . Accordingly, when identifying potential biomarkers for PIBD, our results suggest that multiomics-based approaches afford enhanced potential to detect putative biomarkers for PIBD compared to microbiome community composition sequence data alone.
炎症性肠病(IBD)包括克罗恩病(CD)和溃疡性结肠炎(UC),是一种慢性胃肠道疾病,在美国每100人中就有1人受其影响。据估计,北美每10万名儿童中有15人受小儿炎症性肠病(PIBD)影响。肠道微生物群(GM)、疾病的遗传易感性和某些环境因素等被认为与发病机制有关。然而,IBD的病理生理学尚未完全明确,诊断生物标志物和有效治疗方法,尤其是针对PIBD的,非常有限。最近的研究表明,这些因素可能相互作用影响疾病发展,多组学方法已成为阐明病理生理学的有前景的工具。我们采用基于宏基因组学、代谢组学和宏转录组学的方法来研究微生物群、其遗传潜力及其活性,以识别与PIBD相关的因素。基于宏基因组学的分析揭示了在UC患者中差异表达的途径,如辛烷氧化和糖酵解。此外,基于宏转录组学的分析表明,UC样本中聚糖降解和双组分系统富集,以及CD和UC样本中内质网、核糖体中的蛋白质加工和蛋白质输出。此外,基于代谢组学的方法揭示了健康个体与PIBD个体之间差异丰富的代谢物模式。有趣的是,总体微生物群群落组成(通过α和β多样性指数衡量)似乎与PIBD无关。然而,我们观察到UC与健康对照之间有少量差异丰富的分类群,包括 纲和 纲的成员以及 科的成员。因此,在识别PIBD的潜在生物标志物时,我们的结果表明,与仅使用微生物群群落组成序列数据相比,基于多组学的方法有更大潜力检测PIBD的假定生物标志物。